Abstract
Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.
Keywords:
Arthritis; Artritis; Aterosclerosis; Atherosclerosis; Brodalumab; IL-17; Ixekizumab; Obesidad; Obesity; Psoriasis; Secukinumab.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Arthritis, Psoriatic / drug therapy
-
Arthritis, Psoriatic / etiology
-
Arthritis, Psoriatic / immunology
-
Clinical Trials as Topic
-
Disease Models, Animal
-
Disease Susceptibility
-
Double-Blind Method
-
Humans
-
Infections / etiology
-
Inflammation / immunology
-
Interleukin-17 / antagonists & inhibitors
-
Interleukin-17 / physiology*
-
Interleukin-23 / immunology
-
Mice
-
Models, Immunological
-
Neoplasms / etiology
-
Psoriasis / drug therapy
-
Psoriasis / etiology*
-
Psoriasis / immunology
-
Randomized Controlled Trials as Topic
-
Receptors, Interleukin-17 / antagonists & inhibitors
-
Receptors, Interleukin-17 / physiology
-
T-Lymphocyte Subsets / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Interleukin-17
-
Interleukin-23
-
Receptors, Interleukin-17
-
brodalumab
-
ixekizumab
-
secukinumab